ASSEMBLY BIOSCIENCES INC (ASMB) Stock News

NASDAQ:ASMB - Nasdaq - US0453962070 - Common Stock - Currency: USD

19.3 +0.34 (+1.79%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ASMB Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Yahoo Finance - Mentions: GILD

Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes

18 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

23 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

23 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

a year ago - By: BusinessInsider

News Image

ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

2 months ago - By: Zacks Investment Research - Mentions: TSHA

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

a year ago - By: Benzinga - Mentions: TTSH

Insiders Buying American Software And 2 Other Stocks

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

2 months ago - By: Zacks Investment Research - Mentions: AMPH

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates

2 months ago - By: Assembly Biosciences, Inc.

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

3 months ago - By: Zacks Investment Research - Mentions: BBIO

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Benzinga - Mentions: ADPT ICAD SYRA BCDA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

10 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

a year ago - By: InvestorPlace

ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024

a year ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

a year ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

a year ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

a year ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

a year ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection